FDA Approves Nypozi (filgrastim-txid), a Biosimilar to Neupogen

July 1, 2024

FDA approves Nypozi (filgrastim-txid), a biosimilar to Neupogen, indicated to decrease the incidence of infection in patients with non-myeloid malignancies.

Highlighted Terms

Tanvex BioPharma, Inc.NEUPOGEN filgrastim-txid Nypozi U.S. Food and Drug Administration Neupogen

Related News

drugs.com

FDA Approves Nypozi (filgrastim-txid), a Biosimilar to Neupogen

FDA approves Nypozi (filgrastim-txid), a biosimilar to Neupogen, indicated to decrease the incidence of infection in patients with non-myeloid malignancies.